SCHEMBL1000214

SCHEMBL1000214

Clc1sc(Oc2ccccn2)nc1-c1cn[nH]c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 4/20 0.45
KCNH2 Q12809 1/20 0.39
ILK Q13418 1/20 0.37
AKT1 P31749 1/20 0.36
AKT2 P31751 1/20 0.36
KDM4E B2RXH2 1/20 0.36
PIN1 Q13526 1/20 0.35
GRM8 O00222 1/20 0.35
FYN P06241 2/20 0.34
PIM1 P11309 2/20 0.33
TNK2 Q07912 1/20 0.32
MAPK14 Q16539 1/20 0.32
SCN9A Q15858 1/20 0.32
AURKA O14965 1/20 0.31
CCNA2 P20248 1/20 0.31
CDK2 P24941 1/20 0.31
TTK P33981 1/20 0.31
IRAK4 Q9NWZ3 1/20 0.31
ADORA2A P29274 1/20 0.30
ADORA1 P30542 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1051493 0.82 GRM4 (0.42) GRM4KCNH2ILKAKT1AKT2
SCHEMBL15049635 0.80 GRM4 (0.37) GRM4KCNH2ILKKDM4E
SCHEMBL1049256 0.74 GRM4 (0.57) GRM4KCNH2ILKAKT1AKT2
SCHEMBL366756 0.74 GRM4 (0.74) GRM4KCNH2GRM8FYN
SCHEMBL368850 0.70 GRM4 (0.56) GRM4KCNH2ILKAKT1AKT2
SCHEMBL1051323 0.69 KLKB1 (0.39) ADORA2AADORA1
SCHEMBL1047866 0.69 CYP11B1 (0.36) GRM4ILKAKT1AKT2MAPK14
SCHEMBL15049877 0.67 GRM4 (0.48) GRM4KCNH2ILKAKT1AKT2
SCHEMBL29590331 0.66 AKT2 (0.46) GRM4KCNH2AKT1AKT2FYN
SCHEMBL27090965 0.66 AKT2 (0.46) GRM4KCNH2AKT1AKT2FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513252-B2 Pyrazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors ADDEX PHARMA S.A. (CH) 2013-08-20 US claimed
EP-2456769-B1 NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2013-06-26 EP claimed
EP-2456769-A1 NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS Addex Pharma SA (CH) 2012-05-30 EP claimed
US-20120122907-A1 Novel Pyrazole Derivatives and their use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors NISSAN MOTOR CO., LTD. (JP) 2012-05-17 US claimed
US-8513252-B2 Pyrazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors ADDEX PHARMA S.A. (CH) 2013-08-20 US disclosed
EP-2456769-B1 NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2013-06-26 EP disclosed
EP-2456769-A1 NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS Addex Pharma SA (CH) 2012-05-30 EP disclosed
US-20120122907-A1 Novel Pyrazole Derivatives and their use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors NISSAN MOTOR CO., LTD. (JP) 2012-05-17 US disclosed
WO-2011010222-A1 NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2011-01-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122907-A1 Novel Pyrazole Derivatives and their use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors GRM1, GRM4, GRM3 GRM4 2/4885KCNH2 1226/4885ILK 4478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.